{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:42:13Z","timestamp":1772134933143,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"publisher","award":["LEC-BHR-P-09-22-926"],"award-info":[{"award-number":["LEC-BHR-P-09-22-926"]}],"id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"publisher","award":["LEC-BHR-P-09-22-926"],"award-info":[{"award-number":["LEC-BHR-P-09-22-926"]}],"id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"publisher","award":["LEC-BHR-P-09-22-926"],"award-info":[{"award-number":["LEC-BHR-P-09-22-926"]}],"id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41433-025-03896-x","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T18:29:18Z","timestamp":1752258558000},"page":"2540-2547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral fundus fluorescein angiogram detects reactivation post anti-VEGF in aggressive retinopathy of prematurity"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4465-4765","authenticated-orcid":false,"given":"Akash","family":"Belenje","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakasi Ugandhar","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-3225","authenticated-orcid":false,"given":"Tapas Ranjan","family":"Padhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-0539","authenticated-orcid":false,"given":"Subhadra","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"3896_CR1","doi-asserted-by":"publisher","first-page":"S533","DOI":"10.1542\/peds.2018-0478C","volume":"142","author":"M Domell\u00f6f","year":"2018","unstructured":"Domell\u00f6f M, Jonsson B. The Swedish approach to management of extreme prematurity at the borderline of viability: a historical and ethical perspective. Pediatrics. 2018;142:S533\u20138.","journal-title":"Pediatrics"},{"key":"3896_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.778585","volume":"10","author":"AV Naravane","year":"2022","unstructured":"Naravane AV, Belin PJ, Rubino S, Quiram PA. Aggressive posterior retinopathy of prematurity: long-term outcomes following intravitreal bevacizumab. Front Pediatr. 2022;10:778585.","journal-title":"Front Pediatr"},{"key":"3896_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0815-1","volume":"18","author":"Q Tong","year":"2018","unstructured":"Tong Q, Yin H, Zhao M, et al. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab. BMC Ophthalmol. 2018;18:150.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"3896_CR4","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1177\/11206721211073405","volume":"32","author":"A Beccasio","year":"2022","unstructured":"Beccasio A, Mignini C, Caricato A, Iaccheri B, Di Cara G, Verrotti A, et al. New trends in intravitreal anti-VEGF therapy for ROP. Eur J Ophthalmol. 2022;32(3):1340\u201351. https:\/\/doi.org\/10.1177\/11206721211073405.","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"3896_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.18240\/ijo.2020.05.17","volume":"13","author":"SD Wang","year":"2020","unstructured":"Wang SD, Zhang GM. Shenzhen screening for retinopathy of prematurity cooperative group. Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis. Int J Ophthalmol. 2020;13(5):806\u201315. https:\/\/doi.org\/10.18240\/ijo.2020.05.17.","journal-title":"Int J Ophthalmol"},{"issue":"7","key":"3896_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1007374.","journal-title":"N Engl J Med"},{"key":"3896_CR7","first-page":"29","volume":"68","author":"R Autrata","year":"2012","unstructured":"Autrata R, Senkov\u00e1 K, Holousov\u00e1 M, Krejc\u00edrov\u00e1 I, Dolezel Z, Borek I. Pr\u00ednos intravitre\u00e1ln\u00ed aplikace anti-VEGF prepar\u00e1t\u016f v l\u00e9cbe prahov\u00e9ho stadia ROP 3+ v z\u00f3ne I-II: v\u00fdsledky ctyrlet\u00e9 studie [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II-four years results]. Cesk Slov Oftalmol. 2012;68:29\u201336.","journal-title":"Cesk Slov Oftalmol"},{"issue":"8","key":"3896_CR8","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000\u20136.","journal-title":"Arch Ophthalmol"},{"key":"3896_CR9","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016;123:1845\u201355.","journal-title":"Ophthalmology"},{"issue":"6","key":"3896_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/IAE.0000000000004067","volume":"44","author":"TR Padhi","year":"2024","unstructured":"Padhi TR, Bhunia S, Shah M, Sahu S, Das T, Bhusal U, et al. Outcome of eyes treated for retinopathy of prematurity in posterior zone i: an Eastern India study. Retina. 2024;44(6):1073\u201382. https:\/\/doi.org\/10.1097\/IAE.0000000000004067.","journal-title":"Retina"},{"key":"3896_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2024.113913","volume":"273","author":"CC Lee","year":"2024","unstructured":"Lee CC, Chiang MC, Chu SM, Wu WC, Ho MM, Lien R. Clinical risk factors for retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor injection. J Pediatr. 2024;273:113913. https:\/\/doi.org\/10.1016\/j.jpeds.2024.113913.","journal-title":"J Pediatr"},{"issue":"12","key":"3896_CR12","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1038\/s41433-021-01413-4","volume":"35","author":"A \u00c7\u00f6mez","year":"2021","unstructured":"\u00c7\u00f6mez A, Karak\u00fc\u00e7\u00fck Y, \u00d6zmen MC, \u00c7elemler P, Sayg\u0131l\u0131 O. The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity. Eye. 2021;35(12):3302\u201310. https:\/\/doi.org\/10.1038\/s41433-021-01413-4.","journal-title":"Eye"},{"key":"3896_CR13","doi-asserted-by":"publisher","unstructured":"Belenje, A, Reddy, RU, Optom, B et al. Non-contact widefield neonatal retinal imaging for retinopathy of prematurity using the Clarus 700 high resolution true colour reflectance imaging. Eye. 2022. https:\/\/doi.org\/10.1038\/s41433-022-02273-2","DOI":"10.1038\/s41433-022-02273-2"},{"key":"3896_CR14","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41433-023-02824-1","volume":"38","author":"A Belenje","year":"2024","unstructured":"Belenje A, Reddy RU, Parmeswarappa DC, et al. Evaluation of optical coherence tomography biomarkers to differentiate favourable and unfavourable responders to intravitreal anti-vascular endothelial growth factor treatment in retinopathy of prematurity. Eye. 2024;38:1097\u2013103.","journal-title":"Eye"},{"key":"3896_CR15","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41433-021-01694-9","volume":"36","author":"A Hans","year":"2022","unstructured":"Hans A, Narang S, Sindhu M, et al. Fundus fluorescein angiography in retinopathy of prematurity. Eye. 2022;36:1604\u20139.","journal-title":"Eye"},{"issue":"5","key":"3896_CR16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.survophthal.2023.05.004","volume":"68","author":"M Kvopka","year":"2023","unstructured":"Kvopka M, Chan W, Lake SR, Durkin S, Taranath D. Fundus fluorescein angiography imaging of retinopathy of prematurity in infants: a review. Surv Ophthalmol. 2023;68(5):849\u201360. https:\/\/doi.org\/10.1016\/j.survophthal.2023.05.004.","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"3896_CR17","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","volume":"128","author":"MF Chiang","year":"2021","unstructured":"Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Paul Chan RV, Berrocal A, et al. International classification of retinopathy of prematurity, third edition. Ophthalmology. 2021;128(10):e51\u2013e68. https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.031.","journal-title":"Ophthalmology"},{"key":"3896_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41433-020-01328-6","volume":"36","author":"OR Marmoy","year":"2022","unstructured":"Marmoy OR, Henderson RH, Ooi K. Recommended protocol for performing oral fundus fluorescein angiography (FFA) in children. Eye. 2022;36:234\u20136.","journal-title":"Eye"},{"key":"3896_CR19","unstructured":"https:\/\/www.optos.com\/products\/silverstone\/"},{"issue":"4","key":"3896_CR20","doi-asserted-by":"publisher","first-page":"F327","DOI":"10.1136\/archdischild-2012-302365","volume":"98","author":"S Jalali","year":"2013","unstructured":"Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities retinopathy of prematurity screening database report number 5. Arch Dis Child Fetal Neonatal Ed. 2013;98(4):F327\u201333.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"11","key":"3896_CR21","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","volume":"41","author":"C Iwahashi","year":"2021","unstructured":"Iwahashi C, Utamura S, Kuniyoshi K, Sugioka K, Konishi Y, Wada N, Kusaka S, et al. Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity. Retina. 2021;41(11):2261\u20138.","journal-title":"Retina"},{"issue":"8","key":"3896_CR22","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41433-021-01694-9","volume":"36","author":"A Hans","year":"2022","unstructured":"Hans A, Narang S, Sindhu M, Jain S, Chawla D. Fundus fluorescein angiography in retinopathy of prematurity. Eye. 2022;36(8):1604\u20139. https:\/\/doi.org\/10.1038\/s41433-021-01694-9.","journal-title":"Eye"},{"key":"3896_CR23","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1097\/IAE.0000000000002761","volume":"40","author":"J Mao","year":"2020","unstructured":"Mao J, Shao Y, Lao J, Yu X, Chen Y, Zhang C, Li H, Shen L, et al. Ultra\u2013wide-field imaging and intravenous fundus fluorescein angiography in infants with retinopathy of prematurity. Retina. 2020;40:2357\u201365.","journal-title":"Retina"},{"key":"3896_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.survophthal.2023.05.004","volume":"68","author":"M Kvopka","year":"2023","unstructured":"Kvopka M, Chan W, Lake SR, Durkin S, Taranath D. Fundus fluorescein angiography imaging of retinopathy of prematurity in infants: a review. Survey Ophthalmol. 2023;68:849\u201360.","journal-title":"Survey Ophthalmol"},{"key":"3896_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49964-8","volume":"14","author":"X Chen","year":"2024","unstructured":"Chen X, Imperio R, Viehland C, et al. A pilot optical coherence tomography angiography classification of retinal neovascularization in retinopathy of prematurity. Sci Rep. 2024;14:568.","journal-title":"Sci Rep."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03896-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03896-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03896-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:56:39Z","timestamp":1757224599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03896-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3896"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03896-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5903788\/v1","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"IRB approved with ethics number LEC-BHR-P-09-22-926.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}